Synthesis and bioassay of 3-Aryl -1-(pyridin-4-yl)benzo[4,5]imidazo[1,2-d][1,2,4]- triazin-4(3H)-ones as anti-cancer agents
Naunyn-Schmiedeberg's Archives of Pharmacology · 2023
DOI: 10.1007/s00210-023-02433-5 ↗Kurz gefasst
Fachartikel in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, 2023. Verfasst von Bassam Abu Thaher und 11 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Science, Chemistry Department, Islamic University of Gaza, P.O. Box 108, Gaza, Palestine. Hauptthemen laut MEDLINE: Antineoplastic Agents, Breast Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 55 Literaturangaben. Gefördert von: Alexander von Humboldt Foundation, Palestinian Research Council.
Abstract (Originalsprache)
Four novel 3-Aryl -1-(pyridin-4-yl)benzo[4,5]imidazo[1,2-d][1,2,4]- triazin-4(3H)-ones derivatives (C1 to C4) have been designed, synthesized, and evaluated for their anticancer activity. The structure of compounds was characterized by IR,1H NMR, 13C NMR and high-resolution mass (HRMS). The crystal structures of C1, C2 and C4 were previously determined by single-crystal X-ray analysis.The results from docking experiments with EGFR suggested the binding of the compounds at the active site of EGFR. The new compounds exhibited different levels of cytotoxicity against HCC1937 and MCF7 breast cancer cells. Results of the MTT assay identified C3 as the most cytotoxic of the series against both MCF7 and HCC1937 breast cancer cell lines with IC50 values of 36.4 and 48.2 µM, respectively. In addition to its ability to inhibit cell growth and colony formation ability, C3 also inhibited breast cancer cell migration. Western blotting results showed that C3 treatment inhibited EGFR signaling and induced cell cycle arrest and apoptosis as indicated by the low level of p-EGFR and p-AKT and the increasing levels of p53, p21 and cleaved PARP. Our work represents a promising starting point for the development of a new series of compounds targeting cancer cells.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Science, Chemistry Department, Islamic University of Gaza, P.O. Box 108, Gaza, Palestine.
- Faculty of Pharmacy, Al-Azhar University, Gaza, Palestine.
- Department of Biology and Biotechnology, Islamic University of Gaza, PO Box 108, Gaza, Palestine. siwini@iugaza.edu.ps.
- Department of Biology and Biotechnology, Islamic University of Gaza, PO Box 108, Gaza, Palestine.
- Division of Bioorganic Chemistry, School of Pharmacy, Saarland University, D-66123, Saarbruecken, Germany.
- Faculty of Medical and Life Sciences, Hochschule Furtwangen (HFU), Jakob-Kienzle-Strasse 17, 78054, Villingen-Schwenningen, Germany. Hans-Peter.Deigner@hs-furtwangen.de.
Förderung
- Alexander von Humboldt Foundation
- Palestinian Research Council
Zitieren
APA
Thaher, B. A., Al-Masri, I., Wahedy, K., Morjan, R., Aliwaini, S., Al Atter, I. M., Elmabhouh, A. A., Ibwaini, A. K. A., Alkhaldi, S. L., Qeshta, B., Jacob, C., & Deigner, H. P. (2023). Synthesis and bioassay of 3-Aryl -1-(pyridin-4-yl)benzo[4,5]imidazo[1,2-d][1,2,4]- triazin-4(3H)-ones as anti-cancer agents. Naunyn-Schmiedeberg's Archives of Pharmacology. https://doi.org/10.1007/s00210-023-02433-5
Vancouver
Thaher BA, Al-Masri I, Wahedy K, Morjan R, Aliwaini S, Al Atter IM, et al. Synthesis and bioassay of 3-Aryl -1-(pyridin-4-yl)benzo[4,5]imidazo[1,2-d][1,2,4]- triazin-4(3H)-ones as anti-cancer agents. Naunyn-Schmiedeberg's Archives of Pharmacology. 2023. doi:10.1007/s00210-023-02433-5
BibTeX
@article{Thaher2023,
author = {Thaher, Bassam Abu and Al-Masri, Ihab and Wahedy, Kanan and Morjan, Rami and Aliwaini, Saeb and Al Atter, Iman Mahmoud and Elmabhouh, Aayat Ahmed and Ibwaini, Areej Khaled Al and Alkhaldi, Saba Luay and Qeshta, Basem and Jacob, Claus and Deigner, Hans-Peter},
title = {Synthesis and bioassay of 3-Aryl -1-(pyridin-4-yl)benzo[4,5]imidazo[1,2-d][1,2,4]- triazin-4(3H)-ones as anti-cancer agents},
journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
year = {2023},
doi = {10.1007/s00210-023-02433-5}
}
EUVIMED